19.7
アンフォテリシンBは、真菌と哺乳類の細胞膜間の構造の違いを利用する広域スペクトルの抗真菌薬です。その両親性構造は、疎水性のポリエン-ラクトーン環と、マイコサミン基およびカルボン酸基を含む親水領域を特徴とし、主に菌類の細胞膜に存在するステロールであるエルゴステロールに選択的に結合することを可能にします…
抗真菌剤は病原性真菌を標的にして感染の拡散を防ぎます。例えば、アンフォテリシンBは真菌細胞膜を標的とする薬剤の一つです。
アンフォテリシンBは両親性分子であり、疎水性と親水性の両方の領域を含みます。
親水性領域のマイコサミン基とカルボン酸基は、真菌の細胞膜に優勢であるエルゴステロールに結合します。この結合により、分子が脂質二重層に挿入されることが安定化します。
挿入後、複数のアンフォテリシン分子が周囲の脂質鎖に整列し、孔状チャネルに組み合わされます。
これらのチャネルはイオン、特にカリウムの制御不能な漏れを許し、浸透圧の不均衡を引き起こし、真菌細胞の死を引き起こします。
別のメカニズムとして、アンフォテリシンB分子は脂質二重層に平行に整列します。
この配向はエルゴステロールを膜表面に向かって隔離し、膜の構造的完全性を乱します。
View the full transcript and gain access to JoVE Core videos
Q1: How does amphotericin B target fungal cells?
Amphotericin B is an amphipathic molecule with hydrophobic and hydrophilic regions that selectively bind to ergosterol, a sterol predominant in fungal plasma membranes. This binding exploits structural differences between fungal and mammalian cell membranes, enabling the drug to disrupt fungal cells while minimizing damage to human cells. The selective interaction with ergosterol underlies amphotericin B's antifungal activity.
Q2: What is the pore-formation mechanism of amphotericin B?
In the pore-formation model, amphotericin B molecules insert into the lipid bilayer and assemble into pore-like channels. Multiple amphotericin molecules align with surrounding lipid chains to form these oligomeric transmembrane channels. The pores allow uncontrolled leakage of intracellular ions, particularly potassium, disrupting ionic gradients and causing fungal cell death.
Q3: How does the surface-aligned model of amphotericin B differ from pore formation?
In the surface-aligned model, amphotericin B binds ergosterol while remaining parallel to the membrane rather than inserting through it. This alignment causes ergosterol clustering at the membrane surface, disrupting lipid organization and compromising membrane integrity without forming pores. This mechanism operates independently of transmembrane channel formation.
Q4: What role do reactive oxygen species play in amphotericin B's antifungal action?
Amphotericin B triggers production of reactive oxygen species (ROS), including superoxide anions, hydrogen peroxide, and hydroxyl radicals. These ROS cause oxidative damage to cellular components such as lipids, proteins, and nucleic acids. This oxidative stress mechanism operates independently of ergosterol binding, providing an additional fungicidal effect beyond membrane disruption.
Q5: What is the sponge model of amphotericin B action?
In the sponge model, amphotericin B aggregates sequester ergosterol into extracellular complexes rather than embedding in the membrane. These aggregates extract ergosterol from the bilayer, depleting it and impairing essential membrane functions. This mechanism represents an alternative pathway to fungal cell death distinct from pore formation or surface alignment.
Q6: Why does amphotericin B cause toxicity in human cells?
Although amphotericin B selectively binds ergosterol in fungal membranes, weak binding to cholesterol, the sterol predominant in mammalian cell membranes, contributes to toxicity in human cells. This off-target interaction with cholesterol can disrupt human cell membranes, limiting the drug's therapeutic window. The structural similarity between ergosterol and cholesterol accounts for this undesired cross-reactivity.
Q7: What structural features of amphotericin B enable its antifungal selectivity?
Amphotericin B's amphipathic structure features a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups. The mycosamine and carboxylic acid groups bind to ergosterol, stabilizing the molecule's insertion into the fungal lipid bilayer. This dual-region architecture allows selective recognition and targeting of fungal-specific membrane components.